UK PrEP decision re-ignites HIV activism.
The Lancet
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000068679:Emtricitabine / Q000008:administration & dosage; D004739:England; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D006291:Health Policy / Q000331:legislation & jurisprudence* / Q000639:trends; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D009313:National Health Programs; D065129:Pre-Exposure Prophylaxis / Q000379:methods / Q000592:standards / Q000639:trends; D011634:Public Health; D000068698:Tenofovir / Q000008:administration & dosage; D006113:United Kingdom / Q000453:epidemiology
D019380:Anti-HIV Agents; D000068698:Tenofovir; D000068679:Emtricitabine